These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 20517473)

  • 1. Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomized, two-arm, open-label, Phase IIIb study.
    Camu W; Hadjout K; Latour S; Pöhlau D; Masri S
    Patient Prefer Adherence; 2010 May; 4():127-33. PubMed ID: 20517473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rebif(®) Quality of Life (RebiQoL): A randomized, multicenter, Phase IIIb study evaluating quality-of-life measures in patients receiving the serum-free formulation of subcutaneous interferon beta-1a for the treatment of relapsing forms of multiple sclerosis.
    Bandari D; Wynn D; Miller T; Singer B; Wray S; Bennett R; Hayward B; Dangond F;
    Mult Scler Relat Disord; 2013 Jan; 2(1):45-56. PubMed ID: 25877454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study.
    Lugaresi A; Florio C; Brescia-Morra V; Cottone S; Bellantonio P; Clerico M; Centonze D; Uccelli A; di Ioia M; De Luca G; Marcellusi A; Paolillo A;
    BMC Neurol; 2012 Mar; 12():7. PubMed ID: 22390218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks.
    Hendin B; Naismith RT; Wray SE; Huang D; Dong Q; Livingston T; Jones DL; Watson C; Jhaveri M
    Patient Prefer Adherence; 2018; 12():1289-1297. PubMed ID: 30050291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study.
    Devonshire V; Arbizu T; Borre B; Lang M; Lugaresi A; Singer B; Verdun di Cantogno E; Cornelisse P
    BMC Neurol; 2010 Apr; 10():28. PubMed ID: 20433746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Peg IFN Beta-1a (Pre-filled Pen) in Subjects With Relapsing-Remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM Study).
    Centonze D; Fantozzi R; Buttari F; Grimaldi LME; Totaro R; Corea F; Marrosu MG; Confalonieri P; Cottone S; Trojano M; Zipoli V
    Front Neurol; 2021; 12():637615. PubMed ID: 33967938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alleviating flu-like symptoms with dose titration and analgesics in MS patients on intramuscular interferon beta-1a therapy: a pilot study.
    Brandes DW; Bigley K; Hornstein W; Cohen H; Au W; Shubin R
    Curr Med Res Opin; 2007 Jul; 23(7):1667-72. PubMed ID: 17588298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Both paracetamol and ibuprofen are equally effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during interferon beta-1a (AVONEX) therapy.
    Reess J; Haas J; Gabriel K; Fuhlrott A; Fiola M
    Mult Scler; 2002 Feb; 8(1):15-8. PubMed ID: 11936482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous interferon-beta-1a : new formulation.
    McKeage K; Wagstaff AJ
    CNS Drugs; 2007; 21(10):871-6. PubMed ID: 17850174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The STAR Study: a real-world, international, observational study of the safety and tolerability of, and adherence to, serum-free subcutaneous interferon β-1a in patients with relapsing multiple sclerosis.
    Hupperts R; Ghazi-Visser L; Martins Silva A; Arvanitis M; Kuusisto H; Marhardt K; Vlaikidis N;
    Clin Ther; 2014 Dec; 36(12):1946-1957. PubMed ID: 24811754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cultural adaptation and validation of a peninsular Spanish version of the MSTCQ
    Muntéis Olivas E; Navarro Mascarell G; Meca Lallana J; Maestre Martínez A; Pérez Sempere Á; Gracia Gil J; Pato Pato A
    Neurologia; 2017; 32(1):29-39. PubMed ID: 25697827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corticosteroids, ibuprofen, and acetaminophen for IFNbeta-1a flu symptoms in MS: a randomized trial.
    Río J; Nos C; Bonaventura I; Arroyo R; Genis D; Sureda B; Ara JR; Brieva L; Martín J; Saiz A; Sánchez López F; Prieto JM; Roquer J; Dorado JF; Montalban X
    Neurology; 2004 Aug; 63(3):525-8. PubMed ID: 15304586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-rated ease of use and functional reliability of an electronic autoinjector for self-injection of subcutaneous interferon beta-1a for relapsing multiple sclerosis.
    Singer B; Wray S; Miller T; Cascione M; Gupta A; Pardo G; Watsky E; Hayward B; Mercer B; Dangond F
    Mult Scler Relat Disord; 2012 Apr; 1(2):87-94. PubMed ID: 25876936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient satisfaction with ExtaviPro™ 30G, a new auto-injector for administering interferon β-1b in multiple sclerosis: results from a real-world, observational EXCHANGE study.
    Hoffmann FA; Trenova A; Llaneza MA; Fischer J; Lus G; von Bredow D; Lara N; Lam E; Van Hoef M; Bakshi R
    BMC Neurol; 2017 Aug; 17(1):156. PubMed ID: 28793876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
    Giovannoni G; Barbarash O; Casset-Semanaz F; Jaber A; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
    Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient satisfaction with an injection device for multiple sclerosis treatment.
    Cramer JA; Cuffel BJ; Divan V; Al-Sabbagh A; Glassman M
    Acta Neurol Scand; 2006 Mar; 113(3):156-62. PubMed ID: 16441244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction in magnetic resonance imaging T2 burden of disease in patients with relapsing-remitting multiple sclerosis: analysis of 48-week data from the EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) study.
    Traboulsee A; Al-Sabbagh A; Bennett R; Chang P; Li DK; ;
    BMC Neurol; 2008 Apr; 8():11. PubMed ID: 18426595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized open label study of pain medications (naproxen, acetaminophen and ibuprofen) for controlling side effects during initiation of IFN beta-1a therapy and during its ongoing use for relapsing-remitting multiple sclerosis.
    Leuschen MP; Filipi M; Healey K
    Mult Scler; 2004 Dec; 10(6):636-42. PubMed ID: 15584488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Administration of subcutaneous interferon beta 1a in the evening: data from RELIEF study.
    Patti F; Zimatore GB; Brescia Morra V; Aguglia U; Bossio RB; Marziolo R; Valentino P; Chisari CG; Capacchione A; Zappia M;
    J Neurol; 2020 Jun; 267(6):1812-1823. PubMed ID: 32140867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results.
    Giovannoni G; Barbarash O; Casset-Semanaz F; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
    Mult Scler; 2009 Feb; 15(2):219-28. PubMed ID: 18755819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.